GYRE Gyre Therapeutics Inc.
Company Analysis
Latest News
Gyre Therapeutics Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
For the second quarter of 2026, analysts expect Gyre Therapeutics to report consensus revenue of $26.49 million and an EPS loss of $0.08, while the stock...
Gyre Therapeutics second quarter 2026 revenue reached $29.1M as China NDA acceptance for F351 progressed
Gyre Therapeutics reported second quarter 2026 revenue of $29.1 million, a 2% year-over-year decrease as growth in core pirfenidone sales was offset by the...
🟢 Gyre Therapeutics is trading 5.17% up today amid broader risk-on market sentiment
Gyre Therapeutics is trading at $6.05 (+5.17%) as of the current session, moving higher despite a lack of company-specific announcements or analyst actions. •...
🔴 Gyre Therapeutics is trading 5.8% down today despite a strong biotech sector
Gyre Therapeutics is trading at $6.05 (5.8% down) today, underperforming a generally strong biotech tape in a move that appears to be stock-specific. • No new...
🔴 Gyre Therapeutics is trading 5.3% down today with no clear catalyst
Gyre Therapeutics is trading 5.3% down at $6.50 today with no fresh, company-specific news hitting the tape to explain the downward move. • Shares appear to...
🟢 GYRE makes sharp 10.9% jump
GYRE is trading at $7.23, up 10.9% versus the comparison close of $6.52 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 GYRE is trading 5.6% up today after filing a resale shelf registration for 30.22 million shares
GYRE is trading 5.6% up at $6.47 amid active trading as investors digest a new shelf registration filing for the potential resale of common stock. • Gyre...
🟢 Gyre Therapeutics Inc. is trading 5.2% up today after stockholders approve preferred stock conversion
Gyre Therapeutics Inc. is trading 5.2% up at $6.12 following stockholder approval for the conversion of Series B Convertible Preferred Stock into common...
GYRE Stockholders Approve Conversion of Series B Preferred Stock at Annual Meeting
Gyre Therapeutics announced that stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 10, 2026. A key approval was the...